17403-09-7

Basic information

• Product Name: 3-Piperidin-4-yl-1H-indole
• Synonyms: 3-PIPERIDIN-4-YL-1H-INDOLE;3-(PIPERID-4-YL)INDOLE;4-(3-INDO)PIPERIDINE;3-(4-PIPERIDINO)INDOLE;3-(4'-PIPERIDINYL)-1H-INDOLE;3-(4-piperidyl)-1H-indole;3-(piperidinyl)Indole;3-(4'-Piperdinyl)-1H-Indole
• CAS NO: 17403-09-7
• Molecular Formula: C₁₃H₁₆N₂
• Molecular Weight: 200.28
• EINECS: 241-425-3
• Product Categories: pharmacetical
• Mol File: 17403-09-7.mol
• Article Data: 18

Chemical Properties

• Melting Point: 222-224°C
• Boiling Point: 386.5 °C at 760 mmHg
• Flash Point: 187.5 °C
• Appearance: /
• Density: 1.15 g/cm³
• Vapor Pressure: 3.03E-06mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 17.06±0.30(Predicted)
• CAS DataBase Reference: 3-Piperidin-4-yl-1H-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Piperidin-4-yl-1H-indole(17403-09-7)
• EPA Substance Registry System: 3-Piperidin-4-yl-1H-indole(17403-09-7)

Safety Data

• Hazard Codes: Xi,C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: 3259
• Hazardous Substances Data: 17403-09-7(Hazardous Substances Data)

Usage

General Description

3-Piperidin-4-yl-1H-indole, also known as PD168077, is a chemical compound that belongs to the indole class of organic compounds. It is a potent and selective agonist for the serotonin receptor 5-HT1E, with a Ki value of 1.6 nM. This receptor is known to be involved in the regulation of neurotransmitter release and may play a role in modulating mood and behavior. Due to its high affinity for the 5-HT1E receptor, PD168077 has been studied as a potential therapeutic agent for the treatment of various neurological and psychiatric disorders, such as depression, anxiety, and schizophrenia. Additionally, it has been used as a pharmacological tool in research to better understand the role of the 5-HT1E receptor in the brain and its potential as a target for drug development.

InChI:InChI=1/C13H16N2/c1-2-4-13-11(3-1)12(9-15-13)10-5-7-14-8-6-10/h1-4,9-10,14-15H,5-8H2/p+1

Upstream product

• 120-72-9 indole 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 155302-28-6 tert.butyl 4-(1H-indol-3-yl)-piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 155302-27-5 3-[N-(t-butyloxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1H-indole 
• 17403-05-3 3-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]-1H-indole 
• 41661-47-6 piperidin-4-one 
• 179234-89-0 3-(1-benzylpiperidin-4-yl)-1H-indole 
• 41979-39-9 4-piperidone hydrochloride 
• 65347-55-9 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole 

Downstream Products

• 423173-96-0 5-[4-(1H-indol-3-yl)-piperidin-1-ylmethyl]-2-methoxy-benzoic Acid Ethyl Ester 

Relevant articles and documents

Synthesis of new bridged tetrahydro-β-carbolines and spiro-fused quinuclidines

Two series of chemically related, conformationally restricted ring systems were synthesized. Bridged tetrahydro-β-carbolines, designed as selective 5-HT receptor ligands, were formed via Pictet-Spengler condensation of cyclic tryptamine precursors. Oxidation of the indole 2-position of the precursors followed by condensation with aldehydes produced spiro-cyclic quinuclidines, containing important muscarine receptor pharmacophores.

Substituted heterocyclic compounds and application of same to medicines

The invention relates to substituted heterocyclic compounds and application of the same to medicines and specifically provides the novel substituted heterocyclic compounds or stereoisomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, and preparation methods thereof. The invention also relates to pharmaceutical compositions containing the compounds and application of the compounds or pharmaceutical compositions to treatment of diseases related to 5-HT6 receptors, especially Alzheimer's disease.

PHARMACEUTICAL COMPOUND

Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X2, X4, X10, and X11 may be the same or different and each is independently selected from C and N; X1, X3, X5, X6, X7, X8, and X9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X4 with the carbon atoms either side of X2 are single bonds, and are only present when X2 is absent, X3 is absent and X4 is C, and when these bonds are present the ring carbons on each side of X2 are not directly bonded to each other; each R1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R1 groups present is such that the valency of X1 is maintained; each R12, R13, R13', R14, R15 and R15 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R16 groups present is such that the valency of X2 is maintained; each R17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R17 groups present is such that the valency of X3 is maintained; each R2, R3, R4, and R5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X6, X7, X8, and X9 are maintained; each R7, R8 and R9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X10, X11, and X5 are maintained; and R6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C1-C6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.